Prescribing Clinical Network

Prescribing Clinical Network

Policy Statement
Botulinum toxin type A for the prevention of headaches in adults with chronic migraine

Policy No:
PCN 338-2018
(replaces PCN 34-2012)

Date of Issue
2⁰ May 2018

Review Date:
May 2021
(Unless new published evidence becomes available before this date OR there is new published national guidance e.g. NICE)

Recommendations:
The Surrey Prescribing Clinical Network recommends the use of botulinum toxin type A for the prevention of headaches in adults with chronic migraine in line with NICE Technology Appraisal (TA260 June 2012).

Prescribing will be by hospital specialists only, in line with NICE TA260 using Blueteq initiation and continuation forms. Botulinum toxin type A will be considered RED on the traffic light system.

Key Considerations:
- Patients will be expected to keep a migraine diary prior to access to botulinum toxin type A and should have documented evidence that they have trialled and failed at least three prior pharmacological prophylaxis therapies
- Botulinum toxin type is a medicine that is excluded from national tariff therefore classed as a specialist only drug

Date taken to
Prescribing Clinical
Network
2⁰ May 2018

Agreed by PCN
members
2⁰ May 2018

Surrey (East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG & Surrey Heath CCG), Crawley CCG and Horsham & Mid-Sussex CCG